依度沙班在生物瓣植入或瓣膜修复术后早期的疗效与安全性:随机临床试验
该前瞻性随机开放标签试验将220例外科生物瓣植入或瓣膜修复术后患者1:1分配至依度沙班(60mg或30mg每日一次)或华法林治疗3个月。改良意向治疗分析显示,依度沙班在主要疗效终点(死亡、临床血栓栓塞事件或无症状心内血栓复合终点)上非劣于华法林,主要安全终点大出血风险两组相当。
要点
- 依度沙班在生物瓣术后早期预防血栓栓塞非劣于华法林。
- 依度沙班大出血风险与华法林相当,非劣效性成立。
- 术后3个月内依度沙班或可替代华法林用于抗凝。
核心结论
- 依度沙班在预防血栓栓塞方面非劣于华法林,且大出血风险与华法林相当。
研究设计与样本
- 220例患者随机分配至依度沙班(60mg或30mg每日一次)或华法林,治疗术后前3个月。
- 改良意向治疗分析纳入218例(每组109例)。
主要发现
- 主要疗效终点在华法林组发生4例(3.7%),依度沙班组0例(风险差-0.0367,95%CI -0.0720至-0.0014,非劣效性P<.001)。
- 主要安全终点大出血在华法林组发生1例(0.9%),依度沙班组3例(2.8%)(风险差0.0183,95%CI -0.0172至0.0539,非劣效性P=.013)。
临床怎么用
- 外科生物瓣植入或瓣膜修复术后早期可考虑使用依度沙班替代华法林抗凝。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(218例),事件数少。
- 仅评估术后3个月内的短期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Early warfarin anticoagulation is recommended in patients undergoing surgical bioprosthetic valve implantation or valve repair. It is unclear whether non-vitamin K antagonist oral anticoagulants can be a full alternative to warfarin. This study aimed to compare efficacy and safety of edoxaban with warfarin in patients early after surgical bioprosthetic valve implantation or valve repair. METHODS: The Explore the Efficacy and Safety of Edoxaban in Patients after Heart Valve Repair or Bioprosthetic Valve Replacement study was a prospective, randomized (1:1), open-label, clinical trial conducted from December 2017 to September 2019. Patients were randomly assigned to receive edoxaban (60 mg or 30 mg once daily) or warfarin for the first 3 months after surgical bioprosthetic valve implantation or valve repair. The primary efficacy outcome was a composite of death, clinical thromboembolic events, or asymptomatic intracardiac thrombosis. The primary safety outcome was the occurrence of major bleeding. RESULTS: Of 220 participants, 218 (109 per group) were included in the modified intention-to-treat analysis. The primary efficacy outcome occurred in 4 patients (3.7%) taking warfarin and none taking edoxaban (risk difference, -0.0367; 95% confidence interval, -0.0720 to -0.0014; P < .001 for noninferiority). The primary safety outcome occurred in 1 patient (0.9%) taking warfarin and 3 patients (2.8%) taking edoxaban (risk difference, 0.0183; 95% confidence interval, -0.0172 to 0.0539; P = .013 for noninferiority). CONCLUSIONS: Edoxaban is noninferior to warfarin for preventing thromboembolism and is potentially comparable for risk of major bleeding during the first 3 months after surgical bioprosthetic valve implantation or valve repair.
引用
- Shim CY, Seo J, Kim YJ, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. J Thorac Cardiovasc Surg. 2021. PMID: 33726903. doi:10.1016/j.jtcvs.2021.01.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。